Comment on ‘Histopathologic evaluation of liver metastases from colorectal cancer in patients treated with FOLFOXIRI plus bevacizumab’

Histopathologic evaluation of liver metastases from colorectal cancer in patients treated with FOLFOXIRI plus bevacizumab

(2013) F Loupakis et al.   BRITISH JOURNAL OF CANCER

Infarct-like Necrosis

(2012) Hector H. Li Chang et al.   AMERICAN JOURNAL OF SURGICAL PATHOLOGY

Tumor Thickness at the Tumor-normal Interface: A Novel Pathologic Indicator of Chemotherapy Response in Hepatic Colorectal Metastases

(2010) Dipen M. Maru et al.   AMERICAN JOURNAL OF SURGICAL PATHOLOGY

Bevacizumab Improves Pathological Response of Colorectal Cancer Liver Metastases Treated with XELOX/FOLFOX

(2010) Markus Klinger et al.   ANNALS OF SURGICAL ONCOLOGY

Impact of bevacizumab on functional recovery and histology of the liver after resection of colorectal metastases

(2010) D. A. Wicherts et al.   BRITISH JOURNAL OF SURGERY

Association of Computed Tomography Morphologic Criteria With Pathologic Response and Survival in Patients Treated With Bevacizumab for Colorectal Liver Metastases

(2009) Yun Shin Chun   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Pathologic Response to Preoperative Chemotherapy: A New Outcome End Point After Resection of Hepatic Colorectal Metastases

(2008) Dan G. Blazer et al.   JOURNAL OF CLINICAL ONCOLOGY